T. Kerre MD, PhD

P58 Immuno-T, a motion comic educating patients and caregivers on how immunotherapy strategies work

From Minis to TRUCKs: are CARs ready for the highway?

SUMMARY

CAR T-cells have revolutionised the treatment of relapsed and refractory B-cell malignancies. Especially in B-ALL, exciting results have been published. This article reviews CAR T-cell design, the optimal T-cell product used, the lymphodepleting regimen preceding the adoptive therapy, successes and toxicities induced by CAR T-cells in clinical trials (especially B cell malignancies), and the future of CARs and their position in the quickly evolving field of targeted therapies and immunotherapy for haematological malignancies.

(BELG J HEMATOL 2017;8(3):94–101)

O.5 Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): an interim analysis from the Belgian Hematology Society (BHS)

O.4 In vitro generation of tumor antigen-specific T cells from patient and healthy donor stem cells

Occurrence of mild spontaneous graft-versus-host disease after autologous stem cell transplantation for multiple myeloma: a case report and review of the literature

Summary

We present the case of a 68 year old woman with multiple myeloma, who developed mild persistent upper and lower gastrointestinal symptoms, together with a rash and abnormal liver function tests, in the early phase post-autologous stem cell transplantation. Pathology findings were compatible with graft-versus-host disease. Local treatment with corticosteroids resulted in a durable remission of the autologous graft-versus-host disease. A literature review reveals an incidence of mild gastrointestinal graft-versus-host disease in 13% of patients after autologous stem cell transplantation. Severe fatal autologous graft-versus-host disease has rarely been reported, and solely in multiple myeloma patients. In this article we discuss incidence, pathophysiology, outcome and treatment of these entities.

(BELG J HEMATOL 2016;7(2):83–6)

Allogeneic stem cell transplantation at ASH 2015

(BELG J HEMATOL 2016; 7(1):48–52)

PP4.5 Functional in vitro evaluation of T cells generated from minor H antigen-TCR transduced human hematopoietic stem cells using the OP9-DL1 coculture system